MAPK13 promotes the progression of papillary thyroid cancer
MAPK13 promotes the malignant biological behavior of PTC cells and is associated with EMT. MAPK13 may be a potential biomarker for treatment.
Authors
- Shuixian Huang (ORCID: https://orcid.org/0009-0003-2674-4972)
- Peipei Qiao (ORCID: https://orcid.org/0000-0003-0552-1940)
- Xiaoping Chen (ORCID: https://orcid.org/0009-0004-5354-8499)
- Yi Zhang (ORCID: https://orcid.org/0000-0003-1539-7322)
- Yongbin Chi
- Zhenzhen Su (ORCID: https://orcid.org/0000-0001-5425-5285)
- Liying Zheng (ORCID: https://orcid.org/0000-0003-2073-4194)
- Zhihan Wan
- Yingying Lu (ORCID: https://orcid.org/0000-0002-7187-1511)
- Ruibing Zhao (ORCID: https://orcid.org/0009-0000-9537-2285)
Institutions
- Shanghai University (CN)
- Shanghai Medical College of Fudan University (CN)
- University of Shanghai for Science and Technology (CN)
- Second Military Medical University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhongshan Hospital (CN)
- Shanghai Pudong New Area Gongli Hospital (CN)
Publication Details
- Journal
- European Thyroid Journal
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1530/etj-25-0083
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00